| Titre : |
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation |
| Type de document : |
texte imprimé |
| Auteurs : |
Cheryl Oncken, Auteur ; David H. Gonzales, Auteur ; Mitchell Nides, Auteur |
| Editeur : |
American Medical Association (AMA) |
| Année de publication : |
2006 |
| Collection : |
Archives of internal medicine, ISSN 0003-9926 num. Vol. 166 |
| Importance : |
p. 1571-1577 |
| Présentation : |
tab., graph. |
| Langues : |
Anglais (eng) |
| Catégories : |
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
|
| Index. décimale : |
TA 6.2.3.1.4 Autres substituts nicotiniques |
| Résumé : |
Abstract
BACKGROUND:
The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation.
METHODS:
This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide-confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52.
RESULTS:
Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation. |
| En ligne : |
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/410803 |
| Format de la ressource électronique : |
HTML |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7951 |
|
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation (2006)
